Cue Biopharma shares surge 30.50% after-hours on $21.9M collaboration revenue and 40% stake in ImmunoScape.

Cue Biopharma surged 30.50% in after-hours trading following the release of its Q4 2025 financial results and business updates. The company reported $21.9 million in Q4 collaboration revenue, primarily from its ImmunoScape partnership, and ended 2025 with $27.1 million in cash. Additionally, it secured a 40% equity stake in ImmunoScape and exceeded Q4 EPS estimates by 110% at $0.01 per share. The results highlighted strategic progress on its lead autoimmune candidate, CUE-401, and underscored financial stability amid R&D advancements. These developments, including robust collaboration revenue and improved profitability, likely drove the sharp post-market rally.